RxSight (RXST) Net Equity Issued and Repurchased (2022 - 2026)

RxSight (RXST) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $144000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 79.31% year-over-year to $144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 70.08% YoY) and the FY2025 annual result came in at $4.0 million, down 81.02% from the prior year.
• Net Equity Issued and Repurchased eased to $144000.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $11.7 million in Q3 2023 to a low of $131000.0 in Q3 2025.
• A 5-year average of $3.0 million and a median of $2.1 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased jumped 7968.97% — and 2025, when it tumbled 96.58%.
• Tracing RXST's Net Equity Issued and Repurchased over 5 years: stood at $589000.0 in 2022, then soared by 508.32% to $3.6 million in 2023, then fell by 16.61% to $3.0 million in 2024, then plunged by 64.66% to $1.1 million in 2025, then sank by 86.36% to $144000.0 in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $144000.0 (Q1 2026), $1.1 million (Q4 2025), and $131000.0 (Q3 2025), per Business Quant data.